To date, the FDA-approved drugs that are utilized to block either PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab, avelumab, and durvalumab), classified under the name “immune checkpoint inhibitors (ICI)”, have made a distinct revolutionary pathway for a successful treatment and improved survival of cancer patients [211,212]. This evidence concerns the gene CD274 and cancer.